NYSE AMERICAN: ZOM

Disclaimer

These materials have been prepared for informational purposes only in relation to Zomedica and are not, under any circumstances, to be construed as an offering of any

securities for sale directly or indirectly in any province or territory of Canada, in the United States or in the territories or possessions thereof. Prospective investors should not

construe the contents of this presentation as legal, tax, financial, investment or other advice. Each investor should make his own inquiries and consult his own advisors as to legal,

tax, financial, investment and related matters concerning Zomedica and any investment therein. The information presented in this presentation is considered to be accurate;

however, there is no expressed or implied representation or warranty as to the accuracy of any such information.

Except for statements of historical fact, this news release contains certain "forward-looking information" within the meaning of applicable securities law. Forward-looking

information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain

events or conditions "may" or "will" occur. Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that

such expectations will prove to be correct. We cannot guarantee future results, performance or achievements. Consequently, there is no representation that the actual results

achieved will be the same, in whole or in part, as those set out in the forward-looking information.

Forward-looking information is based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties

and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information. Some of the risks and other factors that

could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: uncertainty as to whether our strategies and

business plans will yield the expected benefits; uncertainty as to the timing and results of development work and pilot and pivotal studies, uncertainty as to the likelihood and

timing of regulatory approvals, availability and cost of capital; the ability to identify and develop and achieve commercial success for new products and technologies; veterinary

acceptance of our products; competition from related products; the level of expenditures necessary to maintain and improve the quality of products and services; changes in

technology and changes in laws and regulations; our ability to secure and maintain strategic relationships; risks pertaining to permits and licensing, intellectual property

infringement risks, risks relating to future clinical trials, regulatory approvals, safety and efficacy of our products, the use of our product, intellectual property protection, risks

related to the COVID-19 pandemic and its impact upon Zomedica’s business operations generally, including Zomedica’s ability to develop its diagnostic products, and the other

risk factors disclosed in our filings with the SEC and under our profile on SEDAR at www.sedar.com. Readers are cautioned that this list of risk factors should not be construed as

exhaustive.

The forward-looking information contained in this document is expressly qualified by this cautionary statement. We undertake no duty to update any of the forward-looking

information to conform such information to actual results or to changes in our expectations except as otherwise required by applicable securities legislation. Readers are

cautioned not to place undue reliance on forward-looking information.

4/24/2020 2

Focus on Novel Companion Animal Diagnostics

• Late-stage development company on verge of commercializing it’s first

major platform, TRUFORMA™

• Bringing the world’s most sensitive detection technologies to pet healthcare

through exclusive partnerships

• Targeting unmet clinical needs

• Management team with more than 100 years veterinary industry experience

• Voice of customer network of over 3,000 veterinary professionals

• Razor – Razor Blade business model with instrument platforms and recurring

consumable revenue

Leadership TeamBased in Ann Arbor, MI, with more than 100 years of cumulative pet healthcare experience

Shameze Rampertab, CPA, CAInterim CEO & CFO

Bridging financial, investment analysis, and life science arenas to drive shareholder value.

Stephanie Morley, DVMPresident & Chief Operations Officer

Building strategic pipeline to give back to fellow vet practitioners.

Bruk HerbstChief Commercial Officer

Harnessing industry-leading expertise to connect vet practitioners with best-in-class solutions.

Johnny Powers, PhDBoard Member and Strategic Advisor

Executive leader with proven track record in medical diagnostics

i4C Innovations

4

Fastest growing segment in pet healthcare

Sources:

Gen Z and Millennials as Pet Market Consumers: Dogs, Cats and Other Pets, Packaged Facts, February 2018

2016 pet owner survey conducted by The Human Animal Bond Research Institute Foundation in partnership with Cohen Research Group (n=1,995 pet owners). Percentages represent those responding “Strongly Agree” of “Agree”

MarketsandMarkets.com, April 2019: https://www.marketsandmarkets.com/Market-Reports/companion-animal-diagnostic-market-173823870.html 5

“I feel that my pet is an

important part of my family”98%

Veterinary Diagnostics is a Very Attractive Market

• Humanization of pets is a rapidly growing global trend

• Millennials spending more on pets than baby boomers

• Pressure on traditional veterinarian revenue streams

• 68% of U.S. households have at least one pet

• 83% of dog-owning households visit the vet every year

• Estimated 170M clinical visits in the U.S. in 2018, growing 3-5% annually

• Trend toward point-of-care diagnostics

• U.S. market $2.8B in 2018 ($4B global), growing ~10% annually over coming years

• Favorable payor and regulatory environments

6

Diagnostic Testing is Essential to a Pet’s Well-BeingPets can’t talk – So they tell us what’s wrong through their test results

In-Clinic Testing✓ Results During Pet Visit

X Often Lacks Ref Lab Accuracy

Remote Reference Lab Testing✓ Highly Accurate Equipment

X 1-5 Day Results Turnaround Time

Unmet Clinical Needs Exist: Lack of Sensitivity/Specificity of Currently Available

In-Clinic Platforms Require Many Tests to be Sent to Remote Reference Labs

Zomedica Platforms Have the Potential to Change the Dynamics for

Veterinarians, Patients and Pet Owners

Results In Minutes Reference Lab

Accuracy

Earlier Diagnosis

& Therapy

Better Patient Outcomes

& Disorder ManagementGreater Confidence &

Control of Cost, Revenue

& Process

Delays results and treatment and often requires multiple vet visits with higher costs for the pet owner

7

Our Inaugural Product

TRUFORMA™ Targeting Ref Lab Quality in a Small In-Clinic Instrument

1. Today, highly accurate results require large, expensive,

sophisticated equipment – only found at a reference lab

2. Existing in-clinic platforms struggle to achieve reference lab

immunoassay accuracy

3. For a confident diagnosis, tests are sent out to a reference lab

– delaying results and taking control away from the veterinary care

team and pet owner

9

Tennis ball scale

Industry Comparison

Siemens Immulite®

TRUFORMA™ is aimed at providing reference quality

results in the clinic during the patient visit

TRUFORMA™ is an investigational device, not currently available for sale and limited to investigational use only.

TRUFORMA™

10

Bulk Acoustic Wave (BAW) SensorMeasures small changes in frequency in response

to binding events

Disposable Cartridge

Pre-Loaded with ReagentsMinimal sample prep

and simple workflow

Designed to Provide

Reference Lab

Quality ResultsTest results in less than 20 min.

Based on Proven Highly Sensitive Bulk Acoustic Wave Technology from

Qorvo Currently used in Telecommunications and Aerospace Industries

70 issued and disclosed patents covering instrument, cartridge, assay development, board and assembly, die and manufacturing

Completion of verification

and validation of initial

assays in 2020

Semiconductor technology

that until now has been

used extensively in the

telecommunications and

aerospace industries

Feasibility results show

excellent performance data

as the product moves into

validation

All marketed assays will

have a time to result <20

minutes

Species CorrelationAnalytical / Dynamic

Range

Immulite 2000®

Reported Range

TSH Canine & Feline 0.95 0.025 - >15 ng/mL 0.03-12ng/mL*

tT4** Canine & Feline >0.95 0.45 - >30 µg/dL 0.5-15ug/dL*

fT4 Canine 0.95 2.3 - >126.4 pmol/L 3.9-77.2 pmol/L

Cortisol Canine 0.96 ~1 – 100 ug/dL 1-50 ug/dL

eACTH Canine n/a n/a n/a

*values only available on canine data only** canine verification data

12

We Estimate ~108K

Worldwide TRUFORMA™

Placement Opportunities,

Driving Recurring Revenue

in Consumables

Sources:IDEXX 2018 Organic Revenue Growth and CAGR data available publicly:

Research https://www.idexx.com/files/20190815 investor day 1130.pdf

Estimates based on current in clinic instrument manufacturer reports and

number of reported clinics

US Clinics Already

Running In-Clinic

Chemistry

International Clinics

Already Running

In-Clinic Chemistry

Greenfield Clinics

Not Running

In-Clinic Chemistry

Today

Total Worldwide

Placement Opportunity

50,000

23,000

108,000

All clinics currently running

in-house chemistry tests are

immediate potential placement

opportunities

35,000

TRUFORMA™ 2020 Controlled Launch PlanDeveloping the market with a thoughtful and targeted roll-out

13

Expected Instrument &

Consumable Revenue:Proven Adoption

Targeted Launch: Select Strategic Markets

Instruments Placed for

Validation Studies:Key Thought Leaders

Instruments Placed

for Pilot Program: Academia & Referral

Q4

Drive Consumable

Utilization: Instrument Placements

Talent:Initiate Onboarding of

Sales Team

Demand Generation:Market Education

Launch Strategic Sites: Influencers, Academia, Emergency

Referral Centers & Corporate Accounts

14

Projected TRUFORMA™ Launch and Menu Expansion TimelineFlexibility of Platform Technology Offers Steady Cadence of New Product Launches and Test Menu Expansion

Launch instrument

with thyroid &

adrenal test menu

(5 tests)

Launch 2

additional tests

non-infectious

GI assays

Launch 2

additional tests

novel renal and

diabetes markers

Launch 2

additional

tests

2020 20232021 2022

Platform Capabilities & Additional Opportunities:

Immunoassays, Molecular Assays, Whole Blood Samples & Multiplexing on the Same Unit

Additional Novel Diagnostic Platforms

and Assays in Development

Targeting Multiple Unmet Clinical Needs

Exclusive Global Veterinary Rights to diagnostic In-Clinic

Biosensor Platform(QRVO: Market Cap $13B)

Exclusive Global Veterinary Rights for novel

pathogen detection system with novel in-clinic diagnostic instrument

Exclusive Global Veterinary Rights for cancer liquid biopsy technology for

veterinary application

16

Zomedica PartnershipsLeveraging leading-edge human technologies and

exclusive partnerships for the global veterinary market

ZM-020 ZM-017 & ZM-022

Cancer

Liquid Biopsy Platform

Single Cell Capture & Analysis

Initial Assays: Osteosarcoma,

Hemangiosarcoma

& Lymphoma

In-Clinic Pathogen

Detection Platform

Unlimited Multiplexing

Initial Assays: 5 Fecal & 12 Urine

Ongoing Assay Development:

Respiratory & Skin Test Menus

17

Additional Novel Platforms & AssaysGlobal Exclusivity – Multiple IP Across Technologies & Species

In-Clinic Pathogen Detection Platform Will Address $600M Fecal Market*

18

Fecal test results in the clinic with potential for reference lab accuracy

Expected Menu• Hookworm

• Roundworm

• Whipworm

• Giardia

• Coccidia

• More than 40M fecal tests run in the U.S. each year*

• In-clinic testing (33M tests annually) utilizes antiquated visual microscopic analysis which lacks

sensitivity/specificity of ref lab testing*

• Ref lab testing (7M tests annually) will not provide a result during the patient visit*

• We believe the Zomedica platform will bring ref lab sensitivity/specificity (or better) to the clinic

• Fully-automated, miniaturized Raman spectroscopy platform capable of broad-based pathogen

identification in minutes developed by Seraph Biosciences, Inc. and Wayne State University

• In-clinic fecal testing will result in better pet outcomes and faster recovery

• Commercial launch expected by 2022

• Expanded menu to include urinalysis testing

* Guggenheim Research Report: “The Fecal Diagnostic Market: Don't Be Afraid to Step in It – October 20, 2019

19

Projected Pathogen Detection Platform Launch TimelineInitial launch for Fecal Pathogen detection, with Urine Pathogen detection added later

Launch Pathogen Instrument

with 5 Panel Fecal Test Menu

2022 2023

Launch 12- Parameter Urine

Test Menu

Canine Cancer Liquid Biopsy Platform

20

First blood test for detection of canine cancer

Initial Menu• Osteosarcoma

• Hemangiosarcoma

• Lymphoma

• 6M dogs develop cancer each year*

• Almost half of dogs over the age of 10 develop cancer**

• Current cancer detection requires expensive imaging testing and invasive biopsies

• Zomedica cancer detection is non-invasive from simple blood draw

• Identification and analysis of rare circulating tumor cells out of millions of cells

• Ref lab platform with results available within 48 hours

• Cutting edge in animal and human medicine

• Development continues for future commercial launch

*https://fetchacure.org/resource-library/facts/

**https://www.avma.org/resources/pet-owners/petcare/cancer-pets

21

2020 Strategic Priorities

• Complete development & validation of the TRUFORMA™

platform with 5 initial assays

• Launch TRUFORMA™ in select target markets and ramp to

commercial revenue

• Continue development of additional high-value

TRUFORMA™ assays

• Advance the development of the fecal platform

• Identify reference lab partner for the cancer platform

• Therapeutic product partnership candidates

2020 & Beyond

22

• Voice of the Vet™

Community (3,000 and growing)

• Academic Institutions

• Key Opinion Leaders

• Sales & Marketing

Team in Place

• Continuing Education

• Key Conferences

• Media Relations

• Preconditioning

TRUFORMA™

In-Clinic Platform

Thyroid Disorders Assays

Free T4: Canine

TSH: Canine & Feline

Total T4: Canine & Feline

Adrenal Disorders

Cortisol: Canine

Endogenous ACTH: Canine

2 First-Ever Point-of-Care

Assays

1. Evergreen Platforms: Finalize

development of fecal/urine and

cancer liquid biopsy platforms

2. International Expansion:

International market is 2x size of US

market

3. Assay Expansion: Add new TRUFORMA™ assays to installed instrument base

4. Other Species: Develop new assays on existing platforms for livestock and poultry applications

Market-Ready

Infrastructure

Industry

Outreach2020

Product Launch

Ongoing Expansion

Beyond 2020

Diagnostic Commercialization and Growth Strategy

Capitalization Table

23

Capital and Financial Information

Cash @ 12/31/19* $0.5 MM

Working Capital Deficit @ 12/31/19* $0.3 MM

Available Unsecured Loan Facility @12/31/19 $5.0 MM

Preferred Shares @ 04/09/20** 12

Warrants @ 04/09/20* 40.2 MM

Common Shares @ 04/09/20* 162.2 MM

Options @ 04/09/20 12.0 MM

Management & Director Ownership @ 04/09/20 14.3 MM

* * The Company closed on February 14, 2020 a registered direct offering of $2.5MM and on April 9, 2020 a public offering of $4.0MM

Exchange NYSE American: ZOM

Market Cap @ 04/23/20 $24.3 MM

Price @ 04/23/20 $0.15

52-Week Range$0.11 Low

$0.50 High

Avg. Daily Volume 11,700,000

** These 12 preferred shares do not have voting rights and are not convertible into common shares

• $4B global market opportunity

• Humanization of pets driving nearly 10% annual market growth

• Diagnostics is the fastest growing sector in pet healthwith few players

• Diagnostic platforms built for sustainable revenue –additional assays to address unmet needs

• Global veterinary exclusivity rights to proven technologies for all species

• First-ever assays

Why Invest in Zomedica

Appendix - Endnotes

25

2016 pet owner survey conducted by The Human Animal Bond Research Institute Foundation in partnership with Cohen Research Group (n=1,995 pet owners). Percentages

represent those responding “Strongly Agree” of “Agree”

MarketsandMarkets.com, April 2019: https://www.marketsandmarkets.com/Market-Reports/companion-animal-diagnostic-market-173823870.html

APPA (American Pet Product Association) Pet Owner Survey

https://fetchacure.org/resource-library/facts/

https://www.avma.org/resources/pet-owners/petcare/cancer-pets

IDEXX 2018 Organic Revenue Growth and CAGR data available publicly: Research https://www.idexx.com/files/20190815 investor day 1130.pdf

Estimates based on current in clinic instrument manufacturer reports and number of reported clinics

Guggenheim Research Report: “The Fecal Diagnostic Market: Don't Be Afraid to Step in It – October 20, 2019

Hypothyroidism in dogs – Panciera DL, Journal of the American Veterinary Medical Association 204(5):761-7 · April 1994, Dixon RM, Epidemiological, clinical, hematological

and biochemical characteristics of canine hypothyroidism, DOI: 10.1136/vr.145.17.481, 1999

Cushing’s Disease in dogs - Horm Res. 2009 Jan;71 Suppl 1:140-3. doi: 10.1159/000178058. Epub 2009 Jan 21. Cushing's disease in dogs and humans.

Feline hyperthyroidism - J Feline Med Surg. 2012 Nov;14(11):804-18. doi: 10.1177/1098612X12464462. Hyperthyroidism in cats: what's causing this epidemic of thyroid

disease and can we prevent it? Peterson M1.

Investor Relations Contacts

26

Zomedica

Shameze Rampertab, Interim CEO, CFO

srampertab@zomedica.com

+1 647.283.3630

PCG Advisory Group

Kirin Smith, COO

ksmith@pcgadvisory.com

+1 646.863.6519